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Clinical Impact of Endoscopic Ultrasound-Fine Needle
Aspiration of Left Adrenal Masses in Established or
Suspected Lung Cancer
Uffe Bodtger, PhD, MD,* Peter Vilmann, MD, DSc,† Paul Clementsen, MD, DSc,*
Elymir Galvis, MD,† Karen Bach, MD,‡ and Birgit Guldhammer Skov, MD, DSc§
Introduction: Correct lung cancer staging is pivotal for optimal
allocation to surgical and nonsurgical treatment. A left adrenal gland
(LAG) mass is found in 5 to 16%, and malignancy preclude surgery.
Endoscopic ultrasound (EUS) is superior to other imaging proce-
dures in visualizing LAG, but the impact of EUS-fine needle
aspiration (FNA) on tumor, node, metastasis (TNM)-staging, treat-
ment, and survival is unknown.
Methods: The impact of EUS-FNA of the LAG on TNM staging,
treatment, and survival was evaluated retrospectively in all patients
(n 40) referred to EUS during 2000–2006 for known or suspected
lung cancer and where EUS disclosed an enlarged LAG. Conven-
tional workup had preceded EUS.
Results: EUS-FNA of an enlarged LAG altered the TNM staging in
70% (downstaged: 26 of 28 patients) and treatment in 48% (gained
surgery 25%, avoided surgery 5%, surgically verified benign disease
5%, no cancer and no further workup 5%, and no cancer, control
computed tomography, and then no further workup 8%). A malig-
nant LAG lesion was found in 28% and was significantly associated
with shorter survival.
Conclusion: EUS-FNA of an enlarged LAG in patients with known
or suspected lung cancer had a significant impact on TNM staging,
treatment, and survival. The impact of routine visualization of the
LAG in lung cancer workup needs to be prospectively validated.
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Lung cancer is the leading cause of cancer-related mortalityin the Western countries, with an estimated annual inci-
dence of 174,000 cases and 162,000 deaths in the United
States.1 Most cases are non-small cell lung cancer (NSCLC),
and correct staging is pivotal for optimal allocation to sur-
gery, which is curative in case of localized disease, whereas
the current recommended treatment in patients with dissem-
inated disease involves chemo- and radiotherapy.2 An adrenal
mass is found at the initial diagnosis of NSCLC in 5 to 16%
of the patients; however, the majority of these masses are
benign adenomas.3,4 Sensitivity and specificity of imaging
techniques are currently insufficient to differentiate benign
from malignant masses, and false-negative and false-positive
rates by computed tomography (CT) scan both average 10%.5
Adrenal masses are traditionally sampled by percutaneous
biopsy, but endoscopic ultrasound (EUS) through the esophagus
is superior to transabdominal ultrasound or CT scan for imaging
the left adrenal gland (LAG).6 EUS-fine needle aspiration (FNA)
and endoscopic bronchial ultrasound-FNA are at present recom-
mended as first choice procedures in invasive staging of medi-
astinal lymph nodes,7 but other relevant lesions are within reach
by EUS too: paraesophagal masses, liver lesions, and LAG
lesions.3,8 The feasibility, safety, yield, and clinical impact of
EUS-FNA in evaluating LAG in patients with established or
suspected lung cancer remains to be systematically reported.
In this study, we aimed at investigating the clinical impact
of EUS-FNA in patients with an established or suspected diag-
nosis of lung cancer and an abnormal LAG at EUS.
PATIENTS AND METHODS
Patients and Design
A retrospective data collection was performed in pa-
tients with established or suspected lung cancer and in whom
EUS disclosed an abnormal LAG (n  40). Patients were
referred for EUS at the Department of Surgical Gastroenter-
ology, Gentofte Hospital, between 2000 and 2006, for either
preoperative staging of established lung cancer or diagnostic
evaluation of CT-verified abnormality of the LAG, parae-
sophagal lesions, and/or enlarged mediastinal lymph nodes.
We routinely visualized the LAG in all patients undergoing
EUS: if abnormal, FNA was performed for a cytologic
diagnosis, and patient data were registered. Patients with right
adrenal gland lesions were excluded from this study, as these
lesions were examined by transabdominal ultrasound. Before
EUS, all patients had undergone an initial workup at the
referring department: CT, bronchoscopic biopsy sampling,
and, when appropriate, transthoracic needle aspiration biopsy
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and/or pleuracentesis. Anonymized data were transferred to
predefined data sheets as recoded categorical or numeral data.
All but two patients were referred from the Department of Chest
Medicine, Gentofte Hospital, the remaining were referred from
two separate centers. All patients gave verbal, informed consent
for the EUS procedure (in Denmark, written consent is not
juridically required before therapy or invasive procedures). The
institutional review board was not consulted because the study is
a retrospective description of an established workup and thus
nonexperimental. The study was conducted according to the
guidelines of the Helsinki declaration and guidelines of the local
Ethical Committee, Copenhagen County, Denmark.
Endpoint
Primary endpoint: clinical impact of EUS, i.e., avoid-
ance of futile surgery or gained surgery due to downstaging
as a consequence of a difference between pre- and post-EUS
tumor, node, metastasis (TNM) staging. “Survival duration”
was stated the June 18, 2008, by searching the regional
Health Care database (Grønt System, Region Hovedstaden,
Denmark) and expressed as months survived after EUS.
Secondary endpoints: complications, diagnostic yield
and diagnostic values of EUS-FNA of LAG, the agreement
with CT findings (dichotome variable: normal/abnormal), and
identification of clinical or paraclinical variables associated
with LAG malignancy.
True diagnostic values of EUS-FNA in the diagnosis of
LAG metastases could not be established, because no surgical
or necropsy biopsies were performed in our study. In absence of
a standard procedure at present, we used “survival2 years” as
a proof of benignancy (i.e., true negative diagnosis), because
adrenal gland metastases are associated with poor survival.
Endoscopic Ultrasound
EUS-FNA was performed on an outpatient basis with the
patient in conscious sedation using midazolam and phentanyl.
The EUS examination was performed with a flexible echoendo-
scope with a curved array transducer, an adjustable ultrasonic
frequency of 5 or 10 MHz, and a penetration depth of 7 to 8 cm
(an Olympus ultrasonic endoscope [GF-UC160P-OL5] con-
nected to an Olympus processor [EU-C60] or an Olympus
[GF-UC140P-AL5] ultrasonic endoscope connected to an Aloka
ultrasound processor [Prosound 5000] or a Pentax [EG 3830]
ultrasonic endoscope connected to an Hitachi ultrasound proces-
sor [EUB 8500]). The LAG and left liver lobe was routinely
inspected first, and if a mass was identified, it was sampled by
FNA first. Lymph nodes were characterized according to
criteria suggestive of malignancy (round shape, hypoechoic,
sharp margin, and size 1 cm). The location was classified
according to the Mountain/Dressler Regional Nodal Stations
for Lung Cancer Staging.9 All lymph nodes with at least one
criterion suggestive of malignancy were sampled (N3- before
N2-lymph nodes). A 22-Gauge needle (MEDI-Globe, Sono-
tip II) was used for the biopsy. EUS-FNA of the LAG was
performed through the cardia of the stomach with 1 to 3
passes of the needle. The aspirated material was smeared onto
glass slides, air dried, and transported to the Department of
Pathology for staining for cytologic evaluation. The patients
were observed for 1 to 2 hours at the hospital after the procedure.
All EUS-FNA examinations were performed by one of three
experienced endosonographers. Possible complications were re-
corded up to 1 year after the procedure. The cytologic specimens
were stained by the May-Gru¨nwald-Giemsa method. Micros-
copy was performed by an experienced cytopathologist
(B.G.S.). The cytologic diagnoses were categorized as follows:
positive for malignancy, benign, or nondiagnostic.
Statistics
All calculations were performed using the SPSS statis-
tical software, version 11.0 (SPSS Inc, Chicago, IL): contin-
uous variables were presented as median and range and
differences analyzed with Mann-Whitney U test. Discrete
variables were presented as number and percentage (n, %)
and differences analyzed with Fisher’s exact test. Statistical
significance was reached when p  0.05.
RESULTS
Patients
Medical records and survival data were available for all
patients (median age 63 [range, 38–79; women n  20;
staging of known NSCLC n  15). Pre-EUS TNM staging
suggested a surgically curable lung neoplasm in two patients
(stage IB and IIB). Table 1 shows that no clinical or en-
dosonographical parameter was significantly associated with
LAG malignancy except malignancy in EUS-FNA specimens
of mediastinal lesions.
Final Diagnoses
Overall, 33 patients (83%) received a final diagnosis of
malignancy: NSCLC (n  29, consisting of nonspecified:
n  17; large cell carcinoma: n  1; adenocarcinoma: n  9;
squamous cell carcinoma: n  2), small cell lung cancer
(SCLC) (n 1), malignant thymoma (n 1), lung metastasis
from femoral myosarcoma (n  1), and unknown primary
neoplasm with cerebral metastases (n  1). In the remaining
seven patients, an initial suspicion of malignancy was abol-
ished after workup. Two patients proceeded to lobectomy,
whereas workup was terminated directly or shortly after EUS
in five patients who all had CT scans showing lesions in
lungs, mediastinal glands, and LAG, and all had benign
EUS-FNA from the two latter locations. In two patients, the
pulmonary lesions were reached by EUS (showing fibrotic
scarring and infection), and workup stopped hereafter. In
three patients, reevaluation of the CT scan performed at a
multidisciplinary meeting (chest surgeon, chest physician,
radiologist, pathologist, and oncologist) with the benign
EUS-FNA data available resulted in an expecting approach:
control CT scan showed resolution of pulmonary tumor.
Left Adrenal Gland
EUS showed a focal lesion (n  36) or an enlarged
gland (n  4; nonhypoechoic and preserved shape). Malig-
nancy was found in LAG biopsies from 11 patients (27%):
NSCLC (n  10) and myosarcoma (n  1) and was signif-
icantly associated with short survival. No between-groups
differences in follow-up length were found (Table 1). Of 29
benign LAG biopsies, 27 (93%) contained representative
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samples of adrenal gland tissue, resulting in a diagnostic yield
of 95% (38 of 40). Benign adrenal hyperplasia was detected
in two samples, and one patient (with enlarged mediastinal
lymph node at CT and a reduced pulmonary mass at control
CT) had a LAG neoplasm: surgical removal confirmed a
benign, mature teratoma. The association and diagnostic rates
of EUS-FNA outcome for 2-year survival are presented in
Table 2. No complications of EUS-FNA were observed.
The majority of our patients had a CT finding of an
abnormal LAG, as this was an inclusion criterion. The positive
and negative predictive values of CT were 0.29 (nine malignant
biopsies/31 abnormal LAG at CT) and 0.78 (seven nonmalig-
nant [normal] biopsies/nine normal LAG at CT), respectively.
The corresponding values for the ultrasonographical diagnosis
of LAG by EUS were 0.31 (11 malignant biopsies/36 abnormal
LAG [focal lesions] at EUS) and 1.0 (four benign biopsies/four
enlarged but otherwise normal LAG at EUS).
Mediastinum
In five patients (12%), mediastinal structures were
considered normal both by EUS and CT, and no samples
were obtained. Mediastinal malignancy was found in 20
patients (suspicion of lung cancer: n  15): 11 of these
patients (55%) had benign LAG samples (NSCLC: n  10;
SCLC: n  1) and nine malignant LAG samples.
Clinical Impact of EUS
Figure 1 depicts the clinical course of our patients.
No Clinical Impact
Pre-EUS TNM stage was unaltered in 12 patients (stage
IV: n  11; stage IIIB: n  1). Downstaging had no clinical
impact in additionally 9 of 26 patients (31%): stage IV to IIIB
(N2/N3 disease [n  6], T4: mediastinal tumor invasion, n 
1); SCLC (n  1); and stage IB but predicted postsurgical
FEV1 0.8 L (n  1).
Avoided Surgery
Two patients had LAG metastases and were thus up-
staged from stage IB and IIB to stage IV. Five patients
avoided further investigation or therapy because EUS (and a
follow-up CT, n  3) disproved intrathoracic and LAG
malignancy, so totally 7 of 40 (18%) avoided futile surgery
(thoracotomy  lobectomy, n  2; resp. mediastinoscopy
and/or video-assisted thoracoscopy FNA, n  5).
Gained Surgery
The remaining 12 patients with an EUS-FNA showing
the patients eligible for surgery underwent surgery, and
malignancy was present in 10 patients (77%). Neither of
these surgically treated patients were pre-EUS staged as
eligible for surgery (downstaged from T2N3M0, n  1; or
stage IV, n  9). Histopathological diagnoses were adeno-
carcinoma (n  5), squamous cell carcinoma (n  1), mixed
subtype adenocarcinoma/squamous cell carcinoma (n  2),
large cell carcinoma (n  1), and malignant thymoma (n 
1). Surgical edges were without malignancy in all but one
patient (malignant infiltration of thoracic soft tissue;
T3N0M0), who subsequently received neoadjuvant chemo-
therapy thus 9/40 (23%) gained surgical treatment. Two
patients (5%) had benign lesions: infected pulmonary infarc-
TABLE 1. Outcome of EUS-FNA of the Left Adrenal Gland:
Demographic, Radiographic, Endoscopic, and Clinical
Variables
Malignancy
(n  11)
No Malignancy
(n  29) pa
Women, n (%) 3 (27) 17 (59) 0.16
Age (yr), median (range) 62 (47–78) 63 (38–79) 0.98
Staging of NSCLC, n (%) 5 (46) 10 (35) 0.72
CT: normal left adrenal
gland, n (%)
2 (18) 7 (24) 1.0
EUS: left adrenal gland
Focal lesion, n (%) 11 (100) 25 (86) 0.56
Hypoechoic, n (%) 10 (91) 23 (92) 1.0
Normal shape, n (%) 0 (0) 4 (14) 0.56
Largest diameter in
mm, median (range)
20 (6–60) 20 (7–50) 0.77
No. of passings, median
(range)
2 (1–3) 2 (1–3) 0.90
EUS-FNA: mediastinal
malignancy, n (%)
9/10 (90) 10/22 (45) 0.05
Malignancy, n (%) 11 (100) 22 (76) 0.16
Lung cancer, n (%) 10 (91) 20 (69) 0.40
Surgery, n (%) 0 (0) 12 (41) 0.005
Survival (mo), median
(range)
6 (1–33) 26 (1–86) 0.005
Follow-up (mo), median
(range)
36 (21–86) 43 (21–86) 0.29
a Fisher’s exact test resp. Mann-Whitney’s U test.
CT, computed tomography; EUS-FNA, endoscopic ultrasound-fine needle aspira-
tion; NSCLC, non-small cell lung cancer.
TABLE 2. Outcome and Diagnostic Rates of EUS-FNA of the Left Adrenal Gland and 2-Yr Survival
EUS-FNA of Left Adrenal Gland
Survival <24 mo
After EUS-FNA
Total Fisher’s Test Predictive ValuesNo Yes
Benign 16 13 29 p  0.05 NPV: 0.55
Malignant 1 10 11 PPV: 0.91
Total 17 23 40
Sensitivity: 0.94 Specificity: 0.43
EUS, endoscopic ultrasound; FNA, fine needle aspiration biopsy; PPV and NPV, positive resp. negative predictive value.
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tion (thoracotomy lobectomy) and unspecific fibrotic tissue
(video-assisted thoracoscopy  wedge resection).
Follow-Up
Table 3 shows the poor survival rates of nonsurgically
treated patients: only one patient (4%) was alive at follow-up
(squamous cell carcinoma, stage IIIB; follow-up duration: 22
months). Among patients with benign disease, 6 of 7 patients
were alive (median follow-up duration: 46 months [range,
31–86 months]): one patient died 12 months after EUS (no
surgery, aged 80 years; nonneoplastic cause of death), giving
a 2-year survival of 86%.
DISCUSSION
This study is, to our best knowledge, the first to dem-
onstrate that EUS-FNA of the LAG profoundly affected
pre-EUS staging of lung cancer and survival by changing
therapeutic management in patients with suspected or con-
firmed lung cancer and with an abnormal LAG at EUS. An
adrenal gland mass is found in 5 to 16% at the time of lung
cancer diagnosis,2,3 we confirmed that EUS-FNA is a safe
procedure with a high diagnostic yield in the diagnosis of left
adrenal masses.3,10–12
The grave prognosis of metastatic lung cancer is well
described,13 and accordingly we found that malignancy of the
LAG obtained by EUS-FNA was associated with short sur-
vival time and thus a high-positive predictive value for death
within 2 years (Table 2). Additionally, we found that M
staging by EUS-FNA of the LAG was significantly associated
with both treatment modality and survival: 10 patients (25%)
suspected as having LAG metastasis by CT went on to
surgery after EUS-FNA was negative, and five patients (13%)
found to have benign disease at EUS-FNA (assisted/con-
firmed by follow-up CT; n  3) and thus avoided further
diagnostic workup. We identified patients with N0 stage but
LAG metastases, so our findings add to those recently re-
ported by Eloubeidi et al.14 who found that nodal staging by
EUS-FNA was significantly associated with treatment mo-
dality and survival in patients with NSCLC. In our study,
nodal staging by EUS-FNA was performed in the same
session as the LAG evaluation, resulting in a slightly pro-
longed EUS procedure while avoiding further LAG workup.
The lower negative predictive value may be due to
false-negative cytologic diagnoses but can also reflect the
high mortality of patients with lung cancer even in absence of
LAG metastases.13,14 Except for one patient with cerebral
metastases from an unknown primary carcinoma but autopsy-
verified primary lung cancer, none in our population had
known disseminated disease before EUS. As in similar stud-
ies, a surgical reference standard was not applicable, and
postmortem LAG diagnosis does not necessarily reflect the
metastatic situation at the time of EUS.3,10–12 At present, the
standard procedure is based on a fusion of data from clinical,
investigative, and imaging sources.1 A highly trained pathol-
ogist examined all specimens and experienced a satisfying yield
of 95%. Stelow et al.10 reported a 100% yield in 24 patients and
Eloubeidi et al.3 100% in 31 patients. In the latter study, LAG
tended to be larger (median 30 versus 20 mm in this study), and
number of passings were higher (five versus two).3
Our study is a descriptive study of lung cancer workup
resulting in EUS-FNA. These 40 patients constituted a mi-
nority, as more than 2000 patients received a diagnosis of
lung cancer in our center during the study period. As stated in
the Patients and Methods section, EUS was restricted to
patients with unresolved diagnostic uncertainties or as a
preoperative assessment in patients with established lung
cancer,1,2 and EUS-FNA was not performed in patients with
a normal LAG when visualized by EUS. Thus, our study
cannot provide reliable incidence, prevalence data on meta-
n=40
}
}
CT: normal LAG, n=4 CT: abnormal LAG, n=36
Stage IV
LAG metastases
n=2
Stage IV
LAG metastases
n=9
Stage IV
CNS metastases
n=2
Stage IIIB
T4 or N2/N3
n=8
SCLC
Normal LAG
n=1
Localised disease
Surgery 
n=10
Localised disease
No surgery 
n=1
No cancer
Surgery 
n=1
No cancer
No surgery 
n=1
No cancer
No surgery 
n=4
No cancer
Surgery 
n=1
Malignancy
Benignancy
FIGURE 1. Flow-chart depicting the
results of CT and EUS-FNA of the left
adrenal gland (LAG), and clinical im-
pact of adding LAG-EUS to the diag-
nostic work-up. Gained surgery:
rounded box, fat frame. Futile sur-
gery: rounded box, thin frame.
Avoided surgery: rectangular box, fat
frame. No clinical impact of EUS: rect-
angular box, thin frame. See text for
additional information. Abbreviations:
LAG, left adrenal gland; SCLC: small
cell lung carcinoma; CT: computed
tomography.
TABLE 3. Treatment Modality and 2-Yr Survival Rate (n),
and Survival Duration (mo) After EUS-FNA in Patients with
Malignancy (n  33)
Treatment
Survival, n Survival Duration (mo)
pa2-Yr Follow-Up Alive Deadb
Surgery,
n  10
8 (80%) 6 (60%) 34 (22–55) 27 (15–43) 0.91
Oncology,c
n  23
3 (13%) 1 (4%) 22 8 (1–40) 0.87
Fisher’s exact
test, p
0.0005 0.005 0.29 0.06
a Mann-Whitney U test.
b Equals follow-up duration.
c Chemotherapy and/or radiotherapy.
EUS-FNA, endoscopic ultrasound-fine needle aspiration.
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static disease to LAG, or agreement of CT findings with
EUS-FNA. Ideally, EUS should have been performed in all
patients with known or suspected lung cancer, but our center did
not have such capacity (currently, chest physicians in our center
are trained in EUS, inspired by the work of Annema et al.15). We
hope that future, prospective studies will give us the precise
frequencies of normal/abnormal findings and finding of stage
IV disease by EUS-FNA. However, we have no reason to
believe that our patients differ clinically from other patients
with known or suspected lung cancer, which is supported by
the low 2-year survival of our patients with disseminated
disease (Tables 2 and 3). Our study supports that the cyto-
logic diagnosis of an abnormal LAG identified by CT—in
patients with suspected or manifest lung cancer—is effi-
ciently achieved by EUS. The diagnostic accuracy of CT
increases when combining with positron emission tomogra-
phy or delayed enhanced CT,4,5 but our data do not add to this
discussion, as positron emission tomography-CT was only
performed in very few patients.
We excluded patients with right adrenal gland lesions,
which are most often more easily reached by FNA guided by
transabdominal ultrasound than by EUS.10 However, recent
and promising case reports suggest that EUS-FNA of a right
adrenal lesion should be attempted in the same session as
mediastinal node staging and other sampling.16,17
This study is, to our knowledge, the largest report on
EUS-FNA of the LAG in patients undergoing lung cancer
workup. Eloubeidi et al.3 reported in 2005 on a subgroup of
patients with lung cancer: EUS-FNA confirmed LAG metasta-
ses in 60% (n 9) with an abnormal LAG (pre-EUS abdominal
imaging) and known (n 13) or suspected (n 2) lung cancer.
A malignant lesion was associated with shorter survival, but data
on pre- and post-EUS TNM staging, prevalence of surgery, and
2-year survival rates were unfortunately not reported.3 In the
same study, abnormal shape and larger diameter were indepen-
dently associated with LAG malignancy (gastrointestinal and
pulmonary cancers pooled), whereas only LAGmalignancy was
associated with survival in a recent study on NSCLC.14 In our
study, LAG malignancy was more prevalent when malignant
mediastinal lesions were present, probably signifying progres-
sion from localized to systemic disease.2 Neither size, shape,
history of cancer, or any other included parameter was associ-
ated with LAG malignancy (Table 1).
In conclusion, our results clearly demonstrated a signifi-
cant impact of EUS-FNA of the LAG on treatment modality and
survival and avoided and gained surgical procedures. This is in
accordance with the impact of EUS-FNA of mediastinal le-
sions.12,18–22 EUS-FNA had a high diagnostic yield and accu-
racy for LAG lesions, it was safe, and had a high-positive
predictive value of death within 2 years. As a consequence of
optimized staging, allocation to correct lung cancer therapy was
rationalized. Our data confirm the value of EUS in lung cancer
workup as stated in recent reviews and recommendations1,7,19,23
and suggest that the LAG should routinely be examined during
EUS and punctured if a mass lesion is outlined. This suggestion
needs to be prospectively evaluated.
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